Acrivon Therapeutics IncNASDAQ:ACRV
- LAST PRICE12.0200
- TODAY'S CHANGE (%)-0.5300 (-4.2231%)
- Bid / Lots11.8600/ 1
- Ask / Lots12.1500/ 3
- Open / Previous Close12.8600 / 12.5500
- Day Range
- 52 Week Range
- Volume10,127
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | ACRV |
|---|---|---|
| 09:32 ET | 1121 | 12.315 |
| 09:36 ET | 100 | 12.12 |
| 09:41 ET | 199 | 12.5 |
| 09:59 ET | 500 | 12.245 |
| 10:42 ET | 872 | 12.15 |
| 11:36 ET | 3879 | 12.22 |
| 12:39 ET | 500 | 12.19 |
| 01:24 ET | 100 | 12.02 |
May 9, 2023
Acrivon Therapeutics Reports Q1 Loss Narrows From Year Earlier, Receives Fast Track Designation From US FDA For Possible Cancer Therapy, from 11:21AM ET on Tuesday May 09, 2023 by MT Newswires
11:21AM ET on Tuesday May 09, 2023 by MT NewswiresBRIEF-Acrivon Therapeutics Reports Q1 2023 Financial Results And Business Highlights, from 8:55AM ET on Tuesday May 09, 2023 by Thomson Reuters
8:55AM ET on Tuesday May 09, 2023 by Thomson ReutersBRIEF-Acrivon Therapeutics Announces FDA Grants Fast Track Designation For Development Of Acr-368 In Platinum-Resistant Ovarian Cancer And Endometrial Cancer, from 8:45AM ET on Tuesday May 09, 2023 by Thomson Reuters
8:45AM ET on Tuesday May 09, 2023 by Thomson ReutersAcrivon Therapeutics Announces FDA Grants Fast Track Designation for Development of ACR-368 in Platinum-Resistant Ovarian Cancer and Endometrial Cancer, from 8:00AM ET on Tuesday May 09, 2023 by GlobeNewswire
8:00AM ET on Tuesday May 09, 2023 by GlobeNewswireAcrivon Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights, from 8:00AM ET on Tuesday May 09, 2023 by GlobeNewswire
8:00AM ET on Tuesday May 09, 2023 by GlobeNewswire
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Acrivon Therapeutics Inc | 275.2M | 0.0x | --- |
Reneo Pharmaceuticals Inc | 275.3M | -3.8x | --- |
Generation Bio Co | 274.5M | -1.7x | --- |
ALX Oncology Holdings Inc | 278.3M | -2.1x | --- |
Nuvectis Pharma Inc | 280.9M | -12.2x | --- |
Fusion Pharmaceuticals Inc | 270.1M | -2.2x | --- |
Company Information
Acrivon Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in developing precision oncology medicines. The Company uses its precision medicine platform, Acrivon Predictive Precision Proteomics (AP3), to develop its pipeline of oncology drug candidates. Its lead clinical candidate, ACR-368, a selective small molecule inhibitor targeting CHK1 and CHK2 with sub single-digit nM and single-digit nM potency. ACR-368 is in Phase II trial across multiple solid tumor types, including platinum-resistant ovarian, endometrial, and bladder cancer. Using its AP3 platform, it has developed a predictive OncoSignature test for ACR-368, called ACR-368 OncoSignature, that can predict patient response to ACR-368 monotherapy, which improves the clinical overall response rate (ORR), and has the potential to enable expedited drug development. The Company is also developing two preclinical drug programs, such as WEE1 inhibitors and PKMYT1 inhibitor.
Contact Information
- Headquarters
- 480 Arsenal Way, Suite 100WATERTOWN, MA, United States 02472
- Phone
- 617-207-8979
- Fax
- 302-636-5454
Executives
- Chairman of the Board, President, Chief Executive Officer
- Peter Blume-Jensen
- Chief Financial Officer
- Rasmus Holm-Jorgensen
- Chief Operating Officer
- Eric Devroe
- Executive Vice President - Business Operations, Director
- Kristina Masson
- Chief Medical Officer
- Erick Gamelin
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $275.2M |
|---|---|
Revenue (TTM) | --- |
Shares Outstanding | 21.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | --- |
Book Value | $7.78 |
P/E Ratio | 0.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
